Download PDF
J Reconstr Microsurg 2016; 32(04): 256-261
DOI: 10.1055/s-0036-1571807
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Effect of Epigallocatechin Gallate on Flap Viability of Rat Perforator Abdominal Flaps

İbrahim Alper Aksakal
1   Department of Plastic, Reconstructive and Aesthetic Surgery, Samsun Education and Research Hospital, Samsun, Turkey
,
İsmail Küçüker
2   Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Mehmet Emin Önger
3   Department of Histology and Embryology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Murat Sinan Engin
2   Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
,
Musa Kemal Keleş
4   Deartment of Plastic, Reconstructive and Aesthetic Surgery, Diskapi Yildirim Beyazit Training and Research Hospital Ankara, Turkey
,
Ahmet Demir
2   Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey
› Author Affiliations
Further Information

Publication History

29 September 2015

21 December 2015

Publication Date:
26 February 2016 (online)

    Permissions and Reprints

Abstract

Background Epigallocatechin gallate (EGCG) is a substance abundant in green tea. In this study, the effects of EGCG on perforator flap viability were investigated.

Methods A total of 40 rats were assigned to four groups of 10 each. In each subject, a 4 × 6 cm abdominal skin flap was raised and adapted back onto its place. In the control group, no further procedures were taken. In the flap group, 40 mg/kg/d EGCG was injected into the flap. In the gavage group, 100 mg/kg/d EGCG was given through a feeding tube. In the intraperitoneal group, 50 mg/kg/d EGCG was injected intraperitoneally. On the 7th postoperative day, flaps were photographed and the viable areas were measured and compared via a one-way analysis of variance.

Results The ratios of viable and contracted flap area were 9.15/12.01, 4.59/16.46, 11.56/11.20, and 11.65/10.77 cm2 for the control, flap group, gavage group, and intraperitoneal group, respectively. While the flap group yielded the worst results in the sense of flap contraction and viability (p < 0.001), the gavage and intraperitoneal groups were significantly better than those of the control group (p = 0.03). Histologically, epidermal, papillary dermal, and capillary tissue volumes were evaluated. In comparison to the control group, the flap group yielded significantly increased epidermal and dermal volumes (p = 0.03), however, these values were significantly decreased (p = 0.04) in the gavage and intraperitoneal groups. Capillary volumes were significantly decreased in EGCG treatment groups (p < 0.01).

Conclusion Our experiment has shown that oral and intraperitoneal administration of EGCG increases the perforator flap viability when compared with controls, while direct injection decreases the viability.

Keywords

perforator flap - epigallocatechin gallate - flap viability - EGCG
 

  • References

  • 1 Bravo FG, Schwarze HP. Free-style local perforator flaps: concept and classification system. J Plast Reconstr Aesthet Surg 2009; 62 (5) 602-608 , discussion 609
    CrossrefPubMedGoogle Scholar
  • 2 Koshima I, Soeda S. Inferior epigastric artery skin flaps without rectus abdominis muscle. Br J Plast Surg 1989; 42 (6) 645-648
    CrossrefPubMedGoogle Scholar
  • 3 Hamdi M, Craggs B, Stoel AM, Hendrickx B, Zeltzer A. Superior epigastric artery perforator flap: anatomy, clinical applications, and review of literature. J Reconstr Microsurg 2014; 30 (7) 475-482
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Wei F-C, Jain V, Suominen S, Chen H-C. Confusion among perforator flaps: what is a true perforator flap?. Plast Reconstr Surg 2001; 107 (3) 874-876
    CrossrefPubMedGoogle Scholar
  • 5 Fichter AM, Borgmann A, Ritschl LM , et al. Perforator flaps—how many perforators are necessary to keep a flap alive?. Br J Oral Maxillofac Surg 2014; 52 (5) 432-437
    CrossrefPubMedGoogle Scholar
  • 6 Kim JA, Formoso G, Li Y , et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem 2007; 282 (18) 13736-13745
    CrossrefPubMedGoogle Scholar
  • 7 Lorenz M, Urban J, Engelhardt U, Baumann G, Stangl K, Stangl V. Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved. Basic Res Cardiol 2009; 104 (1) 100-110
    CrossrefPubMedGoogle Scholar
  • 8 Chiu AE, Chan JL, Kern DG, Kohler S, Rehmus WE, Kimball AB. Double-blinded, placebo-controlled trial of green tea extracts in the clinical and histologic appearance of photoaging skin. Dermatol Surg 2005; 31 (7 Pt 2): 855-860 , discussion 860
    PubMedGoogle Scholar
  • 9 Kim H, Kawazoe T, Matsumura K, Suzuki S, Hyon SH. Long-term preservation of rat skin tissue by epigallocatechin-3-o-gallate. Cell Transplant 2009; 18 (5) 513-519
    PubMedGoogle Scholar
  • 10 Cheon YW, Tark KC, Kim YW. Better survival of random pattern skin flaps through the use of epigallocatechin gallate. Dermatol Surg 2012; 38 (11) 1835-1842
    CrossrefPubMedGoogle Scholar
  • 11 Tokuda H, Takai S, Matsushima-Nishiwaki R , et al. (—)-epigallocatechin gallate enhances prostaglandin F2alpha-induced VEGF synthesis via upregulating SAPK/JNK activation in osteoblasts. J Cell Biochem 2007; 100 (5) 1146-1153
    CrossrefPubMedGoogle Scholar
  • 12 Cao J, Liang H, Ma A, Liu Y, Ge N, Yao H. Effect of EGCG on the proliferation and invasion of human hepatoma HepG2 cells [in Chinese]. Wei Sheng Yan Jiu 2013; 42 (3) 460-465
    PubMedGoogle Scholar
  • 13 Gu JW, Makey KL, Tucker KB , et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression. Vasc Cell 2013; 5 (1) 9
    CrossrefPubMedGoogle Scholar
  • 14 Hashimoto O, Nakamura A, Nakamura T , et al. Methylated-(3″)-epigallocatechin gallate analog suppresses tumor growth in Huh7 hepatoma cells via inhibition of angiogenesis. Nutr Cancer 2014; 66 (4) 728-735
    CrossrefPubMedGoogle Scholar
  • 15 Koh CH, Lee HS, Chung SK. Effect of topical epigallocatechin gallate on corneal neovascularization in rabbits. Cornea 2014; 33 (5) 527-532
    CrossrefPubMedGoogle Scholar
  • 16 Lee HS, Jun JH, Jung EH, Koo BA, Kim YS. Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation. Molecules 2014; 19 (8) 12150-12172
    CrossrefPubMedGoogle Scholar
  • 17 Luo HQ, Xu M, Zhong WT , et al. EGCG decreases the expression of HIF-1α and VEGF and cell growth in MCF-7 breast cancer cells. J BUON 2014; 19 (2) 435-439
    PubMedGoogle Scholar
  • 18 Moyle CW, Cerezo AB, Winterbone MS , et al. Potent inhibition of VEGFR-2 activation by tight binding of green tea epigallocatechin gallate and apple procyanidins to VEGF: relevance to angiogenesis. Mol Nutr Food Res 2015; 59 (3) 401-412
    CrossrefPubMedGoogle Scholar
  • 19 Shirakami Y, Shimizu M, Adachi S , et al. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 2009; 100 (10) 1957-1962
    CrossrefPubMedGoogle Scholar
  • 20 Okşar HS, Coşkunfirat OK, Ozgentaş HE. Perforator-based flap in rats: a new experimental model. Plast Reconstr Surg 2001; 108 (1) 125-131
    CrossrefPubMedGoogle Scholar
  • 21 Peng PH, Ko ML, Chen CF. Epigallocatechin-3-gallate reduces retinal ischemia/reperfusion injury by attenuating neuronal nitric oxide synthase expression and activity. Exp Eye Res 2008; 86 (4) 637-646
    CrossrefPubMedGoogle Scholar
  • 22 Senthil Kumaran V, Arulmathi K, Srividhya R, Kalaiselvi P. Repletion of antioxidant status by EGCG and retardation of oxidative damage induced macromolecular anomalies in aged rats. Exp Gerontol 2008; 43 (3) 176-183
    CrossrefPubMedGoogle Scholar
  • 23 Altunkaynak BZ, Onger ME, Altunkaynak ME, Ayranci E, Canan S. A Brief Introduction to Stereology and Sampling Strategies: Basic Concepts of Stereology. Neuroquantology 2012; 10 (1) 31-43
    PubMedGoogle Scholar
  • 24 Cruz-Orive LM, Weibel ER. Recent stereological methods for cell biology: a brief survey. Am J Physiol 1990; 258 (4 Pt 1): L148-L156
    PubMedGoogle Scholar
  • 25 Gundersen HJ. Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc 1986; 143 (Pt 1): 3-45
    CrossrefPubMedGoogle Scholar
  • 26 Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147 (Pt 3) 229-263
    CrossrefPubMedGoogle Scholar
  • 27 Baddeley A, Jensen EBV. Stereology for Statisticians. Boca Raton, FL: CRC Press; 2004
    CrossrefGoogle Scholar
  • 28 Kaplan JL, Allen RJ. Cost-based comparison between perforator flaps and TRAM flaps for breast reconstruction. Plast Reconstr Surg 2000; 105 (3) 943-948
    CrossrefPubMedGoogle Scholar
  • 29 Bliss RM. Brewing up the latest tea research. Agric Res 2003; 51 (9) 10
    PubMedGoogle Scholar
  • 30 Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003; 133 (10) 3275S-3284S
    PubMedGoogle Scholar
  • 31 Katiyar SK, Mukhtar H. Tea antioxidants in cancer chemoprevention. J Cell Biochem Suppl 1997; 27: 59-67
    PubMedGoogle Scholar
  • 32 Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2002; 2 (6) 350-359
    CrossrefPubMedGoogle Scholar
  • 33 Trevisanato SI, Kim YI. Tea and health. Nutr Rev 2000; 58 (1) 1-10
    PubMedGoogle Scholar
  • 34 Yang CS, Chung JY, Yang G, Chhabra SK, Lee MJ. Tea and tea polyphenols in cancer prevention. J Nutr 2000; 130 (2S, Suppl): 472S-478S
    PubMedGoogle Scholar
  • 35 Zhu BH, Zhan WH, Li ZR , et al. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 2007; 13 (8) 1162-1169
    CrossrefPubMedGoogle Scholar
  • 36 Kim H, Kawazoe T, Han DW , et al. Enhanced wound healing by an epigallocatechin gallate-incorporated collagen sponge in diabetic mice. Wound Repair Regen 2008; 16 (5) 714-720
    CrossrefPubMedGoogle Scholar
  • 37 Aslan C, Melikoglu C, Ocal I, Saglam G, Sutcu R, Hosnuter M. Effect of epigallocatechin gallate on ischemia-reperfusion injury: an experimental study in a rat epigastric island flap. Int J Clin Exp Med 2014; 7 (1) 57-66
    PubMedGoogle Scholar
  • 38 Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 2006; 78 (18) 2073-2080
    CrossrefPubMedGoogle Scholar